GammaTile®: Surgically targeted radiation therapy for glioblastomas

Research output: Contribution to journalReview articlepeer-review

Abstract

Glioblastoma is the most common primary malignant neoplasm of the central nervous system in adults. Standard of care is resection followed by chemo-radiation therapy. Despite this aggressive approach, >80% of glioblastomas recur in proximity to the resection cavity. Brachytherapy is an attractive strategy for improving local control. GammaTile® is a newly US FDA-cleared device which incorporates 131Cs radiation emitting seeds in a resorbable collagen-based carrier tile for surgically targeted radiation therapy to achieve highly conformal radiation at the time of surgery. Embedding encapsulated 131Cs radiation emitter seeds in collagen-based tiles significantly lowers the technical barriers associated with traditional brachytherapy. In this review, we highlight the potential of surgically targeted radiation therapy and the currently available data for this novel approach.

Original languageEnglish (US)
Pages (from-to)2445-2455
Number of pages11
JournalFuture Oncology
Volume16
Issue number30
DOIs
StatePublished - Oct 2020

Keywords

  • GammaTile
  • STaRT
  • brachytherapy
  • central nervous system
  • glioblastoma
  • radiation therapy

PubMed: MeSH publication types

  • Journal Article

Fingerprint Dive into the research topics of 'GammaTile<sup>®</sup>: Surgically targeted radiation therapy for glioblastomas'. Together they form a unique fingerprint.

Cite this